A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer

PHASE4CompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

erlotinib [Tarceva]

150 mg, orally once a day for up to 6 cycles of 21 days each

DRUG

vinorelbine

60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles

Trial Locations (1)

Taipei

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01196078 - A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter